FINWIRES · TerminalLIVE
FINWIRES
Eli Lilly and Company

Eli Lilly and Company

$LLY
NYSEHealthcare

147 stories mentioning Eli Lilly and CompanyUpdated 7h ago

Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.

Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.7%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Cigna (CI) shares fell 1.6% after Barclays downgraded the stock to equalweight from overweight, and lowered its price target to $304 from $310.Brazil on Tuesday cleared pharmaceutical company EMS to sell the country's first generic version of Novo Nordisk's (NVO) Ozempic shot, Bloomberg reported. EMS plans to sell the generic version, called Ozivy, for 30% less than Ozempic, and it expects it to hit the market within 30 days, the report said. Novo shares were down 1.5%.Eli Lilly (LLY) said it has struck deals to buy three vaccine developers in all-cash deals with a combined value of up to $3.83 billion to build its infectious disease portfolio. Lilly shares rose 0.5%.CG Oncology (CGON) shares fell 3.8% after the firm said that Ambaw Bellete, its president and chief operating officer, will exit the company, effective June 30.

$CGON$CI$LLY$NVO
Sectors

Sector Update: Healthcare Stocks Decline Tuesday Afternoon

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.5%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Brazil on Tuesday cleared pharmaceutical company EMS to sell the country's first generic version of Novo Nordisk's (NVO) Ozempic shot, Bloomberg reported. EMS plans to sell the generic version, called Ozivy, for 30% less than Ozempic, and it expects it to hit the market within 30 days, the report said. Novo shares were down 1.4%.Eli Lilly (LLY) said it has struck deals to buy three vaccine developers in all-cash deals with a combined value of up to $3.83 billion to build its infectious disease portfolio. Shares rose 1.3%.CG Oncology (CGON) shares declined 2.9% after the firm said that Ambaw Bellete, its president and chief operating officer, will exit the company, effective June 30.BioRestorative Therapies (BRTX) shares jumped 18% after the firm said it has completed dosing in its phase 2 trial assessing BRTX-100 to treat chronic lumbar disc disease.

$BRTX$CGON$LLY$NVO
Wire

Top Midday Stories: Micron's Market Cap Briefly Hits $1 Trillion; Qualcomm Reportedly Strikes AI Chip Deal With ByteDance

The Nasdaq Composite and S&P 500 were up, while the Dow Jones Industrial Average was down slightly to kick off a shortened week of trading due to the holiday weekend.In company news, Micron Technology's (MU) market capitalization eclipsed $1 trillion for the first time Tuesday after several bullish analyst reports. Micron shares were up 16% around midday.Qualcomm (QCOM) is set to supply ByteDance with millions of chips for AI data centers to support the TikTok owner's AI agent software under a new deal the companies struck, Bloomberg reported Tuesday, citing people familiar with the matter. Qualcomm shares were up over 5%.Ferrari (RACE) has launched a new all-electric sports car called Luce, the company said Monday. The four-door model includes four electric motors, a 122 kWh battery and electric all-wheel drive, delivering 0-100 km/h acceleration in 2.5 seconds, the company said. The EV's starting price is 550,000 euros ($640,000), multiple media outlets reported. Ferrari shares were down 4.7%.Eli Lilly (LLY) has agreed to acquire Curevo, LimmaTech Biologics and Vaccine Company in deals worth up to nearly $3.83 billion in total, the company said Tuesday. The deals include potential payments of up to $1.5 billion for Curevo, up to $780 million for LimmaTech and up to $1.55 billion for Vaccine Company, the company said. Eli Lilly shares were up 1.2%.BP (BP) said Tuesday its board unanimously decided to remove Albert Manifold as chair and director, effective immediately. BP shares were down 4.6%.AutoZone (AZO) reported fiscal Q3 net income Tuesday of $38.07 per diluted share, up from $35.36 a year earlier and above the FactSet consensus analyst estimate of $36.21. Fiscal Q3 net sales were $4.84 billion, up from $4.46 billion a year ago but below the FactSet consensus of $4.86 billion. AutoZone shares were down 11.3%.Modine Manufacturing (MOD) on Tuesday said it signed a major long-term agreement with one of its strategic data center customers to supply its Airedale cooling solutions. Under the terms of the agreement, Modine said it will reserve production capacity to supply over $4 billion worth of Airedale by Modine cooling products between 2027 and 2029. The customer has also provided an upfront payment of $165 million to support capacity expansion and other investments required to meet future demand, the company said. Modine shares were up 19%.American Airlines Group (AAL) said Tuesday it is installing SpaceX's Starlink to provide wireless internet on over 500 of its narrowbody aircraft starting in Q1 2027. American Airlines shares were up 6%.Price: $872.85, Change: $+121.85, Percent Change: +16.23%

$AAL$AZO$BP$LLY$MOD$MU$QCOM$RACE
Commodities

Exchange-Traded Funds, Equity Futures Rise Pre-Bell Tuesday Amid Renewed Hopes Around Middle East Peace Deal

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7% and the actively traded Invesco QQQ Trust (QQQ) was 1% higher in Tuesday's premarket activity amid renewed hopes of peace between the US and Iran after President Trump said talks are "proceeding nicely."US stock futures were higher, with S&P 500 Index futures up 0.7%, Dow Jones Industrial Average futures advancing 0.6%, and Nasdaq futures gaining 1% before the start of regular trading.The Chicago Federal Reserve Bank's monthly National Activity Index rebounded to a reading of 0.14 in April from minus 0.15 in March, compared with expectations for a smaller gain to minus 0.03 in survey of analysts compiled by Bloomberg as of 7:30 am ET.The Philadelphia Federal Reserve Bank's monthly nonmanufacturing activity index declined to minus 23.6 in May from minus 16.5 in the previous month, compared with the expectations for an increase to minus 13 in a survey compiled by Bloomberg, indicating more widespread contraction in the sector.The Case-Shiller National Home Price index rose by 0.7% in March before seasonal adjustment following a 0.3% increase in February.Consumer confidence data for May is due at 10 am ET.The Dallas Fed's manufacturing reading for May will be released at 10:30 am ET.In premarket activity, bitcoin was down by 0.1%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.8% higher, Ether ETF (EETH) advanced 2.9%, and Bitcoin & Ether Market Cap Weight ETF (BETH) retreated by 0.4%.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.7%, while the Vanguard Industrials Index Fund (VIS) lost 0.03%, and the iShares US Industrials ETF (IYJ) was flat.Elbit Systems (ESLT) stock was up more than 10% before the opening bell after the company reported higher Q1 non-GAAP earnings and revenue.Winners and Losers:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.4%. Direxion Daily Financial Bull 3X Shares (FAS) was up 1.2%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.1% lower.FinVolution (FINV) shares were up more than 5% pre-bell after the company reported higher-than-expected Q1 adjusted earnings and net revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.1% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) gained by 0.02%. The iShares US Consumer Staples ETF (IYK) was down 0.6%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increased by 0.6%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 0.3% higher.Ferrari (RACE) shares were down more than 3% pre-bell a day after the company said it has launched a new all-electric Luce sports car, expanding its lineup with a dedicated electric platform.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) increased by 1.5%, and the iShares US Technology ETF (IYW) was 1.2% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 1.5%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) gained by 4.1%, while the iShares Semiconductor ETF (SOXX) rose by 2.8%.WeRide (WRD) shares were up more than 1% in premarket activity after the company said it will operate its autonomous Robobus at the Roland-Garros for a third consecutive year with Renault Group.EnergyThe iShares US Energy ETF (IYE) was flat, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 1.2%.Eni (E) stock was down more than 2% before the opening bell a day after falling 1.4% at the prior close. The company and its partners, Petroci and Vitol, approved the final investment decision for Cote d'Ivoire's Baleine Phase 3 project, advancing development of the country's largest hydrocarbon discovery.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.4%, the Vanguard Health Care Index Fund (VHT) was up 0.6%, while the iShares US Healthcare ETF (IYH) gained by 0.9%. The iShares Biotechnology ETF (IBB) was 0.4% higher.Eli Lilly (LLY) stock was up more than 1% premarket after the company said it agreed to acquire Curevo, LimmaTech Biologics and Vaccine in deals worth up to nearly $3.83 billion in total.CommoditiesFront-month US West Texas Intermediate crude oil advanced by 1.2% to $97.49 per barrel on the New York Mercantile Exchange. Natural gas was down 1.2% at $2.98 per 1 million British Thermal Units. The United States Oil Fund (USO) retreated by 0.7%, while the United States Natural Gas Fund (UNG) was 0.9% lower.Gold futures for July retreated by 0.5% to $4,521.20 an ounce on the Comex. Silver futures declined by 0.8% to $76.09 an ounce. SPDR Gold Shares (GLD) was down by 0.4%, and the iShares Silver Trust (SLV) fell by 1.3%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$E$EEM$EETH$ESLT$EXI$FAS$FAZ$FINV$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LLY$PMR$QQQ$RACE$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$WRD$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare Stocks Advance Premarket Tuesday

Healthcare stocks were advancing premarket Tuesday, with the iShares Biotechnology ETF (IBB) 0.4% higher and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.Eli Lilly (LLY) has agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Company in deals worth up to nearly $3.83 billion in total, expanding its presence in infectious disease prevention, the company said. Shares of Eli Lilly were up more than 1% pre-bell.Natera (NTRA) stock was up more than 2% after the company said it has upgraded its Panorama non-invasive prenatal test using SNP-informed deep sequencing to improve accuracy in samples with low fetal fraction.Jade Biosciences (JBIO) has dosed the first participant in its phase 2 trial of experimental therapy, JADE101, for immunoglobulin A nephropathy, or IgAN, the drugmaker said. Shares of Jade Biosciences were up more than 5% premarket.

$IBB$JBIO$LLY$NTRA$XLV
Eli Lilly to Acquire Three Vaccine Developers for Up to $3.83 Billion
US Markets

Eli Lilly to Acquire Three Vaccine Developers for Up to $3.83 Billion

Eli Lilly (LLY) will acquire three vaccine developers in all-cash deals with a combined value of up to $3.83 billion, as the drugmaker aims to strengthen its infectious disease portfolio.The pharmaceutical giant on Tuesday agreed to purchase Curevo for up to $1.5 billion, LimmaTech Biologics for up to $780 million and Vaccine Company for up to $1.55 billion, including upfront and subsequent payments upon meeting certain milestones. Eli Lilly's shares were up 1.2% in the most recent premarket activity.The transactions will expand the company's research and development efforts in infectious diseases and reflect its strategy of investing in differentiated technology platforms, it said."These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," Eli Lilly Chief Scientific and Product Officer Daniel Skovronsky said in a statement. "Combining these companies' platforms and teams with Lilly's global scale positions us to change that trajectory."The acquisition of Curevo will give Eli Lilly access to its lead product candidate, amezosvatein, which is currently being developed for the prevention of shingles in adults. "Lilly's global development and commercialization capabilities will accelerate and expand upon amezosvatein's significant potential," Curevo Chief Executive George Simeon said in a separate statement.Switzerland-based LimmaTech is developing vaccines against bacterial pathogens, with its LTB-SA7 lead program currently in phase 1 development as a vaccine against staphylococcus aureus. Vaccine Company's lead program is applying in vivo nanoparticle technologies to the Epstein-Barr virus, with a five-antigen phase 1-ready candidate.Last month, Eli Lilly agreed to acquire clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion to bolster its cancer treatment portfolio. Earlier in the year, Lilly announced an up to $7.8 billion deal to purchase UK-based Centessa Pharmaceuticals and also agreed to buy Orna Therapeutics, a biotechnology company focused on engineering immune cells, for up to $2.4 billion.In April, the drugmaker raised its full-year outlook and reported better-than-expected first-quarter results.

$LLY
Asia Markets

Progress on Potential Middle East Peace Agreement Drives US Equity Futures Higher Pre-Bell

US equity futures were edging higher pre-bell Tuesday as traders monitored the US-Iran situation for a potential peace agreement to end the Middle East war.Dow Jones Industrial Average futures were 0.5% higher, S&P 500 futures were up 0.7%, and Nasdaq futures were 1.1% higher.US Secretary of State Marco Rubio said that negotiations could "take a few days." Both sides said they have made progress on a potential memorandum of understanding that would end the war and provide 60 days for negotiators to reach a final deal.The framework of the memorandum is focused on halting the war and the US naval blockade in exchange for Iran ensuring safe transit in the Strait of Hormuz, according to Iranian foreign ministry spokesperson Esmaeil Baghaei.Traders observed the latest round of earnings, with AutoZone (AZO) reporting an increase in fiscal Q3 net income and net sales.Oil prices were mixed, with front-month global benchmark North Sea Brent crude up 3% at $96.22 per barrel and US West Texas Intermediate crude 3.9% lower at $92.84 per barrel.The Chicago Federal Reserve Bank's monthly National Activity Index rebounded to a reading of 0.14 in April from negative 0.15 in March, compared with expectations for a smaller gain to negative 0.03 in survey of analysts compiled by Bloomberg as of 7:30 am ET.The March S&P Case-Shiller home price index is scheduled for release at 9 am ET. The May consumer confidence index, due at 10 am ET, is projected to fall to 92.0 from 92.8.In other world markets, Japan's Nikkei closed 0.3% lower, Hong Kong's Hang Seng ended flat, and China's Shanghai Composite finished 0.2% lower. Meanwhile, the UK's FTSE 100 was up 0.5% and Germany's DAX index was 0.4% lower in Europe's early afternoon session.In equities, Eli Lilly (LLY) shares were up 1.2% after the company said its experimental gene-editing therapy, VERVE-102, reduced LDL cholesterol and PCSK9 protein levels in a phase 1 study involving adults with heterozygous familial hypercholesterolemia or premature coronary artery disease. BHP Group (BHP) stock was 1.4% higher after a Guardian report that the company scrapped plans for an iron ore processing facility near its Jimblebar mine in Western Australia that was expected to improve ore quality and lower emissions.On the losing side, energy majors ExxonMobil (XOM), Chevron (CVX), and Occidental Petroleum (OXY) saw their shares decline after oil prices fell below $100 for the first time in weeks. ExxonMobil shares were down 1.1%, Chevron stock was 1.2% lower, and Occidental Petroleum shares also fell 1.2%.

Dow JonesNasdaq CompositeS&P 500$AZO$BHP$CVX$LLY$OXY$XOM
Sectors

Sector Update: Health Care

Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3%.Eli Lilly (LLY) has agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Company in deals worth up to nearly $3.83 billion in total, expanding its presence in infectious disease prevention, the company said. Shares of Eli Lilly were up more than 1% pre-bell.

$LLY
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.3%.The iShares Biotechnology ETF (IBB) was fractionally lower.In corporate news, Eli Lilly (LLY) shares rose 2.5% after it said Friday that a new analysis from two phase 3 trials showed that its GLP-1 pill Foundayo at all doses tested was linked to "clinically significant" weight loss in adults 65 years old and older with obesity or overweight.Novo Nordisk's (NVO) Ozempic and Eli Lilly's Mounjaro are being linked to better cancer outcomes in four new studies, The Wall Street Journal reported. The weight-loss and diabetes drugs suggest they could reduce tumor progression, lower overall chance of death, and avert the risk of developing breast cancer, the report said. Novo shares added 1%.Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer. Merck shares jumped 5.6%.Gilead Sciences (GILD) shares gained 2.9%. The company has received approval from the US Food and Drug Administration for Hepcludex to treat chronic hepatitis delta virus infection in adults without advanced liver scarring, or with compensated cirrhosis, the FDA said Friday.

$GILD$LLY$MRK$NVO
Sectors

Sector Update: Healthcare Stocks Gain Friday Afternoon

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer. Merck shares jumped 5%.Eli Lilly (LLY) shares rose 2.2% after it said Friday that a new analysis from two phase 3 trials showed that its GLP-1 pill Foundayo at all doses tested was linked to "clinically significant" weight loss in adults 65 years old and older with obesity or overweight.Novo Nordisk's (NVO) Ozempic and Eli Lilly's Mounjaro are being linked to better cancer outcomes in four new studies, The Wall Street Journal reported. The weight-loss and diabetes drugs suggest they could reduce tumor progression, lower overall chance of death, and avert the risk of developing breast cancer, the report said. Novo shares added 1%.

$LLY$MRK$NVO
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding about 0.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, West Pharmaceutical Services (WST) shares rose 3.1% after the company said it has restored its core enterprise systems following a recent cybersecurity attack.Eli Lilly (LLY) shares added 2.6% after the company said its investigational retatrutide delivered "clinically meaningful" weight loss in a phase 3 trial, where all doses met the primary and key secondary endpoints at 80 weeks.Hims & Hers Health (HIMS) said Thursday that it has launched generic semaglutide for eligible customers in Canada. Its shares gained 2.7%.Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported. Moderna shares were down 1.5%.

$HIMS$LLY$MRNA$WST
Wire

Jefferies Lifts Eli Lilly Price Target to $1,330 From $1,300

Eli Lilly (LLY) has an average rating of buy and mean price target of $1,247.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $1038.83, Change: $+19.96, Percent Change: +1.96%

$LLY
Sectors

Sector Update: Healthcare Stocks Rise Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.5%.The iShares Biotechnology ETF (IBB) was up 0.6%.In corporate news, Eli Lilly (LLY) shares rose 2.1% after the company said its investigational retatrutide delivered "clinically meaningful" weight loss in a phase 3 trial, where all doses met the primary and key secondary endpoints at 80 weeks.Hims & Hers Health (HIMS) said Thursday that it has launched generic semaglutide for eligible customers in Canada. Its shares popped 3.3%.Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported. Moderna shares were down 1.5%.

$HIMS$LLY$MRNA
Sectors

Sector Update: Healthcare

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.5%.The iShares Biotechnology ETF (IBB) was up 0.6%.In corporate news, Eli Lilly (LLY) shares rose 2.3% after it said Thursday its investigational triple hormone receptor agonist retatrutide delivered "clinically meaningful" weight loss in a phase 3 obesity trial, where all doses met the primary and key secondary endpoints at 80 weeks.

$LLY
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding 0.4%.The iShares Biotechnology ETF (IBB) was shedding 1.6%.In corporate news, Boston Scientific (BSX) shares jumped 6% after it said Monday that it invested $1.5 billion for an approximately 34% stake in privately held MiRus, gaining an exclusive option to acquire the company's TAVR business. Separately, Boston Scientific entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase (JPM) as part of its $5 billion share buyback authorization.Claritev (CTEV) shares jumped past 19% after the company issued a response to a Thursday media article stating that the Department of Justice has launched a criminal probe into Claritev. The company said Monday it has not been informed by the DOJ that it is the target of an investigation at no point in the subsequent two years after receiving a 2024 subpoena.Eli Lilly (LLY) was among the pharmaceutical firms highlighted in Monday's Supreme Court order list, which included widespread denials of certiorari in drugmaker-related and other commercial cases, according to the Court's May 18 orders. Lilly shares fell 1.7%.Berkshire Hathaway (BRK.A, BRK.B) said Friday in a regulatory filing that it sold all of its stake in UnitedHealth (UNH). UnitedHealth shares were down 0.8%.

$BSX$CTEV$LLY$UNH
Sectors

Sector Update: Healthcare Stocks Advance Monday Afternoon

Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Healthcare Select Sector SPDR ETF (XLV) up 0.3%.The iShares Biotechnology ETF (IBB) was shedding 1.5%.In corporate news, Claritev (CTEV) shares jumped 28% after the company issued a response to a Thursday media article stating that the Department of Justice has launched a criminal probe into Claritev. The company said Monday it has not been informed by the DOJ that it is the target of an investigation at no point in the subsequent two years after receiving a 2024 subpoena.Eli Lilly (LLY) was among the pharmaceutical firms highlighted in Monday's Supreme Court order list, which included widespread denials of certiorari in drugmaker-related and other commercial cases, according to the Court's May 18 orders. Lilly shares fell 1.4%.Berkshire Hathaway (BRK.A, BRK.B) said Friday in a regulatory filing that it sold all of its stake in UnitedHealth (UNH). UnitedHealth shares were down 1.4%.

$CTEV$LLY$UNH
Wire

Market Chatter: Dell Added 1,000 AI Factory Customers Last Quarter

Dell Technologies' (DELL) AI Factory added 1,00 customers in the past quarter, bringing the total to 5,000 for its product line of servers used to power artificial intelligence work with Nvidia's (NVDA) chips, software and services, Bloomberg reported Monday, citing an interview with Chief Executive Michael Dell.Eli Lilly (LLY), Honeywell International (HON) and Samsung are among its customers, the report said. Dell had about 4,000 clients when it reported its quarterly results in February.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $239.90, Change: $-2.09, Percent Change: -0.87%

$DELL$HON$LLY$NVDA
Wire

Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals

Eli Lilly (LLY) was among the pharmaceutical firms highlighted in Monday's Supreme Court order list, which included widespread denials of certiorari in drugmaker-related and other commercial cases, according to the Court's May 18 orders.The Court vacated and remanded several cases, including voting rights disputes, while rejecting review in multiple pharmaceutical and healthcare-related petitions, reducing the likelihood of near-term Supreme Court intervention in those matters.The Court granted review in one education case while denying dozens of appeals across civil, criminal, regulatory, and healthcare matters, with Justice Sotomayor separately concurring in the denial of certiorari in a sentencing case in which relief had already been granted.Shares of Eli Lilly were down 2.2% in Monday trading.Price: $985.25, Change: $-19.68, Percent Change: -1.96%

$LLY
Sectors

Sector Update: Health Care Stocks Mixed Wednesday Afternoon

Health care stocks were mixed Wednesday afternoon, with the NYSE Health Care Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.1%.The iShares Biotechnology ETF (IBB) climbed 1.8%.In corporate news, CVS Health (CVS) raised its full-year earnings outlook after reporting better-than-expected Q1 results driven by improvement in its health-care benefits segment. Its shares gained 6.8%.Novo Nordisk (NVO) expects generic versions of its Ozempic medication to face approval delays in China until next year, Bloomberg reported, citing the drugmaker. The patent for semaglutide, the main ingredient in Ozempic and Wegovy, expired in China in March, but the company said it still has regulatory data protection until April 2027 due to a trade agreement between China and Switzerland, Bloomberg reported. Novo shares rose 2.5%.Eli Lilly (LLY) is looking to raise about $8 billion from an investment-grade bond sale to fund an acquisition spree, Bloomberg reported. Lilly shares added 0.3%.

$CVS$LLY$NVO
Wire

Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions

(Updates with the company's response in the fourth paragraph.)Eli Lilly (LLY) is looking to raise about $8 billion from an investment-grade bond sale to fund an acquisition spree, Bloomberg reported Wednesday, citing people with direct knowledge of the matter.The company is offering notes in as many as eight tranches, with maturities ranging from two to 40 years, according to the report.Proceeds will be used for general corporate purposes and potentially fund all or part of the upfront cash consideration and related expenses linked to the Centessa Pharmaceuticals (CNTA) and Kelonia Therapeutics acquisitions, Bloomberg said.An Eli Lilly spokesperson said the company is excited to be in the investment-grade market. Following strong Q1 earnings, an upgrade from S&P to AA- with a positive outlook, and a favorable market backdrop, Lilly is encouraged by investor interest, the spokesperson added.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $992.35, Change: $+3.48, Percent Change: +0.35%

$CNTA$LLY

Showing 81-100 of 147

Track with the FINWIRES app suite

FolioX
FolioX
Track Eli Lilly and Company in your portfolio
WheelAI
WheelAI
Analyze Eli Lilly and Company options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Eli Lilly and Company